News
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
Avadel (AVDL) Q2 Revenue Jumps 64%
Avadel Pharmaceuticals Plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to improve lives, released its earnings for Q2 2025 on August 7, 2025. The headline news is
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211039390/en/
Evolution of Visual Acuity in the REFLECT Phase III
VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting